Volume 150, Issue 1, Pages 27-34 (July 2016) Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System  Robert C. Bourge, MD, Aaron B. Waxman, MD, PhD, Mardi Gomberg-Maitland, MD, Shelley M. Shapiro, MD, PhD, James H. Tarver, MD, Dianne L. Zwicke, MD, Jeremy P. Feldman, MD, Murali M. Chakinala, MD, Robert P. Frantz, MD, Fernando Torres, MD, Jeffrey Cerkvenik, MS, Marty Morris, MS, Melissa Thalin, RN, BSN, MBA, Leigh Peterson, PhD, Lewis J. Rubin, MD  CHEST  Volume 150, Issue 1, Pages 27-34 (July 2016) DOI: 10.1016/j.chest.2015.11.005 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Implantation location of the drug delivery system. CHEST 2016 150, 27-34DOI: (10.1016/j.chest.2015.11.005) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Plasma treprostinil levels at baseline and 1 week postimplantation (r = 0.91; P < .0001). CHEST 2016 150, 27-34DOI: (10.1016/j.chest.2015.11.005) Copyright © 2016 The Authors Terms and Conditions